Trastuzumab and breast cancer: Developments and current status

被引：91

作者：

Tokunaga E. ^{[1
]}

Oki E. ^{[1
]}

Nishida K. ^{[1
]}

Koga T. ^{[1
]}

Egashira A. ^{[1
]}

Morita M. ^{[1
]}

Kakeji Y. ^{[1
]}

Maehara Y. ^{[1
]}

机构：

[1] Department of Surgery and Science, Graduate School of Medical Science, Kyushu University, Higashi-ku, Fukuoka 812-8582

来源：

International Journal of Clinical Oncology | 2006年 / 11卷 / 3期

关键词：

Breast cancer; HER2; Molecular-targeted therapy; Trastuzumab;

D O I：

10.1007/s10147-006-0575-4

中图分类号：

学科分类号：

摘要：

The emergence of trastuzumab has drastically changed therapy for breast cancer. Trastuzumab (Herceptin; Genentech) is a recombinant humanized monoclonal antibody that targets an epitope in the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a member of a family of four transmembrane receptor tyrosine kinases that regulate cell growth, survival, and differentiation via multiple signal transduction pathways. Overexpression of HER2 or amplification of the HER2 gene occurs in 20%-30% of human breast cancers. Preclinical models have demonstrated that this antibody has significant antitumor activity as a single agent, and it also has a synergy with certain chemotherapeutic drugs. Phase II and III clinical trials performed in women with metastatic breast cancers that overexpress HER2 have shown trastuzumab to have clinical activity when used as monotherapy, while also improving survival when used as a first-line therapy in combination with chemotherapy. At present, clinical investigations are focusing attention on the efficacy of trastuzumab in both the adjuvant and neoadjuvant setting, as well as in the metastatic setting. In this review, we describe the developments and current status of trastuzumab-based treatment for breast cancer. © The Japan Society of Clinical Oncology 2006.

引用

页码：199 / 208

页数：9

共 85 条

[1]

Yarden Y., Sliwkowski M.X., Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2, pp. 127-137, (2001)

[2]

Slamon D.J., Clark G.M., Wong S.G., Et al., Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, pp. 177-182, (1987)

[3]

Slamon D.J., Godolphin W., Jones L.A., Et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, pp. 707-712, (1989)

[4]

Muss H.B., Thor A.D., Berry D.A., Et al., C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer, N Engl J Med, 330, pp. 1260-1266, (1994)

[5]

Paik S., Bryant J., Park C., Et al., ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer, J Natl Cancer Inst, 90, pp. 1361-1370, (1998)

[6]

Thor A.D., Berry D.A., Budman D.R., Et al., ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer, J Natl Cancer Inst, 90, pp. 1346-1360, (1998)

[7]

De Placido S., De Laurentiis M., Carlomagno C., Et al., Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer, Clin Cancer Res, 9, pp. 1039-1046, (2003)

[8]

Vogel C.L., Cobleigh M.A., Tripathy D., Et al., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J Clin Oncol, 20, pp. 719-726, (2002)

[9]

Slamon D.J., Leyland-Jones B., Shak S., Et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, pp. 783-792, (2001)

[10]

Hudziak R.M., Lewis G.D., Winget M., Et al., P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor, Mol Cell Biol, 9, pp. 1165-1172, (1989)

← 1 2 3 4 5 6 7 8 9 →